Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what training healthcare professionals are given on the impacts of diethylstilbestrol.

On 12 December 2025, Professor Peter Johnson, the National Clinical Director for Cancer, sent a letter to all cancer alliances highlighting the effects of diethylstilbestrol (DES). The message was meant for healthcare professionals, including general practitioners, and referenced existing National Health Service guidance on screening. The Government encourages all women, including those exposed to DES in utero, to attend regular cervical screening which tests for human papilloma virus, the cause of most cervical cancers. The guidance also states that local arrangements, such as regular colposcopy, should be made for women who believe or know they were exposed to DES in utero.

Employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver safe and effective treatment for patients.

The Department does not have any plans to establish a public inquiry into the effects of DES. The Department is currently collaborating with the National Institute for Health and Care Research to explore opportunities for research into the long-term and intergenerational effects of DES, including DES grandchildren.